Not recruitingISRCTN64695913
Safety and efficacy trial of two doses of lurasidone in acutely psychotic subjects with schizophrenia (PEARL 3)
Research studyAges 18+Multiple countries
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.
- Listed locations
- Colombia · Germany and 6 more locations
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Dainippon Sumitomo Pharma America Inc. (USA)
- Sponsor type
- Pharmaceutical company
- Study type
- Other
- Intervention type
- Other / unclear
- Locations
- United States, Colombia, Germany, ...
- Age range
- Over 18 Years
- Official registry ID
- ISRCTN64695913
- Official title
Show the full official title
Safety and efficacy trial of two doses of lurasidone in acutely psychotic subjects with schizophrenia (PEARL 3)
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Colombia · Germany · India
5 more locations
- Philippines
- Romania
- Russia
- Ukraine
- United States
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Dainippon Sumitomo Pharma America Inc. (USA), a pharmaceutical company.
Who can participate?
This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as not recruiting.
